GENE ONLINE|News &
Opinion
Blog

2022-08-25| PolicySpecial

Mounting Criticisms of FDA’s Accelerated Approval Pathway Could Prompt Changes to the System

by Reed Slater
Share To

The FDA instituted its Accelerated Approval Program in 1992 in response to the AIDS epidemic to provide treatment options for life-threatening diseases faster than traditional drug approval pathways. Since then, hundreds of drugs have gone through the expedited pathway, with drug makers vowing to undergo additional clinical trials after approval to confirm the safety and efficacy of the therapies. Despite that promise, many companies put off these studies, called confirmatory trials, for months or years, profiting off drugs that have not proven their efficacy.

Accelerating drug approvals is a double-edged sword. On one side, the process allows patients with few to no other options a chance to receive treatment for life-threatening diseases. On the other hand, the hastened process does not provide enough time for a thorough investigation, bringing drugs to the market that may not actually benefit the patient and, in a worst-case scenario, potentially harm the patient. 

GO Prime with only $1.49 now

LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top